1150 Eastlake Ave E Suite 400 Seattle, Washington 98109, USTherapeutics
Umoja Biopharma develops off-the-shelf, pluripotent stem cell–derived immune effector cell therapies for oncology. The company combines iPSC engineering, genetic modification, and scalable manufacturing to produce standardized allogeneic cell therapy products and support clinical development.
Leadership & Board
- Current Number of Employees
- 254
- Current LinkedIn Followers
- 24,958
Latest Estimated Valuation
- Total Amount Raised
- $100M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $100M
- Latest Funding Round
- Series C
Employee Trend
Umoja Biopharma had 254 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
254Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Umoja Biopharma had 24,958 followers as of November 9, 2026. The number of followers increased by 56 (0.22%) week-over-week.
24,958Latest Followers Count
56(0.22%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Feb 14, 2025 | Series C | $100.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Double Point Ventures | Series C |
| DCVC Bio | Series C |
Similar Companies
A snapshot of private companies similar to Umoja Biopharma, helping you discover and navigate related company profiles.
